LBRX (LB Pharmaceuticals) Tariff Resilience Score: 0/10 (As of Jun. 29, 2026)


LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $32.64
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals Tariff Resilience Score?

LB Pharmaceuticals has the Tariff Resilience Score of 0, which implies that the company might have .

LB Pharmaceuticals has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes LB Pharmaceuticals might have .

LB Pharmaceuticals  (NAS:LBRX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

LB Pharmaceuticals Tariff Resilience Score Related Terms

LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.64
Price